Povidone-iodine in the treatment of burn patients.
The improvement in infusion therapy of burn patients in the last decades has led to a marked reduction of the early mortality rate and to an increase in the importance of severe wound infection and septicaemia. For the control of infection, detailed bacteriological monitoring is recommended. The main therapeutic fields for prevention of infection are: immunotherapy, antisepsis, aseptic techniques, and rapid restoration of the destroyed body surface. The most important part of antisepsis in burns is topical treatment. The good bacteriological and clinical results with povidone-iodine (PVP-I), in combination with open treatment are described. A possible disadvantage of this therapy was the extensive iodine resorption. However, no disorders of thyroid function were revealed, and the TRH test indicated no abnormal reactions of the hypothalamus-pituitary axis. The high serum and urine iodine levels returned rapidly to normal after discontinuing the PVP-I application.
Zellner
P R
PR
Bugyi
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control; D002056:Burns / Q000188:drug therapy*; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced; D007455:Iodine / Q000097:blood / Q000652:urine; D008875:Middle Aged; D011205:Povidone / Q000031:analogs & derivatives*; D011206:Povidone-Iodine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D013997:Time Factors
D000891:Anti-Infective Agents, Local; D011206:Povidone-Iodine; D007455:Iodine; D011205:Povidone; D012837:Silver Sulfadiazine